Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for Visceral Adiposity in COPD
NCT01701934Phase 2Terminated
- Sponsor
- Université Laval
- Start
- Feb 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roflumilast in chronic obstructive pulmonary disease (COPD), metabolic syndrome, sponsored by Université Laval. Started Feb 2013; status: terminated.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)metabolic syndrome
Beyond the preview
Go deeper on NCT01701934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01701934.